+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Genmab AS - logo

Genmab is a leading biotechnology company that focuses on developing innovative antibody products. Arzerra is the company’s first marketed antibody and is approved to treat chronic lymphocytic leukemia (CLL) patients in all major markets. Another product, Darzalex, has been approved in the United States for the treatment of patients with multiple myeloma. Genmab was founded in Copenhagen, Denmark in 1999 and employs around 200 people.

Fallopian tube cancer - Pipeline Insight, 2024 - Product Thumbnail Image

Fallopian tube cancer - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 80 Pages
  • Global
From
From
From
From
From
Malignant Glioma - Pipeline Insight, 2024 - Product Thumbnail Image

Malignant Glioma - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
Immuno-Oncology - Thematic Research - Product Thumbnail Image

Immuno-Oncology - Thematic Research

  • Report
  • May 2022
  • 167 Pages
  • Global
From
Gastric Cancer - Pipeline Review, H2 2020 - Product Thumbnail Image

Gastric Cancer - Pipeline Review, H2 2020

  • Drug Pipelines
  • October 2020
  • 2657 Pages
  • Global
From
From
From
Pharmaceutical Market in Denmark 2024-2028 - Product Thumbnail Image

Pharmaceutical Market in Denmark 2024-2028

  • Report
  • February 2024
  • 139 Pages
  • Denmark
From
From
From
From
Factor II (Prothrombin) Inhibitor - Pipeline Insight, 2024 - Product Thumbnail Image

Factor II (Prothrombin) Inhibitor - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
Loading Indicator